Robbie Marcus
Stock Analyst at JP Morgan
(4.15)
# 528
Out of 4,711 analysts
151
Total ratings
58%
Success rate
10.93%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NPCE NeuroPace | Maintains: Overweight | $9 → $14 | $11.53 | +21.42% | 4 | Dec 17, 2024 | |
| BVS Bioventus | Upgrades: Neutral | $12 → $13 | $10.67 | +21.84% | 3 | Dec 17, 2024 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Overweight | $125 → $128 | $107.12 | +19.49% | 5 | Dec 17, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $110 | $88.95 | +23.66% | 13 | Dec 16, 2024 | |
| PODD Insulet | Maintains: Overweight | $280 → $330 | $266.57 | +23.79% | 4 | Dec 12, 2024 | |
| CBLL CeriBell | Initiates: Overweight | $32 | $26.92 | +18.87% | 1 | Nov 5, 2024 | |
| SYK Stryker | Maintains: Overweight | $375 → $420 | $364.60 | +15.19% | 8 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Overweight | $30 → $40 | $30.72 | +30.21% | 5 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $72 → $78 | $74.81 | +4.26% | 4 | Oct 25, 2024 | |
| DXCM DexCom | Maintains: Neutral | $75 → $85 | $80.04 | +6.20% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $495 → $575 | $524.43 | +9.64% | 4 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $78.91 | +14.05% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $43.12 | +15.96% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $42 | $29.50 | +42.37% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.79 | - | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $6.96 | +14.94% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $36 → $13 | $12.11 | +7.35% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $75 | $68.63 | +9.28% | 5 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $100 → $120 | $93.44 | +28.42% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $62 | $33.66 | +84.19% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $242.54 | +3.08% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $13.60 | +17.65% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.48 | -17.45% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $340 → $181 | $187.77 | -3.61% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $56 → $43 | $21.80 | +97.25% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $18.00 | -5.56% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $114.23 | +3.30% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $90.39 | +72.59% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $81.03 | +29.58% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $150.88 | -73.49% | 2 | May 5, 2020 |
NeuroPace
Dec 17, 2024
Maintains: Overweight
Price Target: $9 → $14
Current: $11.53
Upside: +21.42%
Bioventus
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $10.67
Upside: +21.84%
Zimmer Biomet Holdings
Dec 17, 2024
Upgrades: Overweight
Price Target: $125 → $128
Current: $107.12
Upside: +19.49%
Boston Scientific
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $88.95
Upside: +23.66%
Insulet
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $266.57
Upside: +23.79%
CeriBell
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $26.92
Upside: +18.87%
Stryker
Oct 30, 2024
Maintains: Overweight
Price Target: $375 → $420
Current: $364.60
Upside: +15.19%
AtriCure
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $30.72
Upside: +30.21%
Edwards Lifesciences
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $74.81
Upside: +4.26%
DexCom
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $80.04
Upside: +6.20%
Oct 11, 2024
Maintains: Overweight
Price Target: $495 → $575
Current: $524.43
Upside: +9.64%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $78.91
Upside: +14.05%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $43.12
Upside: +15.96%
Aug 7, 2024
Maintains: Neutral
Price Target: $44 → $42
Current: $29.50
Upside: +42.37%
Aug 7, 2024
Downgrades: Underweight
Price Target: n/a
Current: $3.79
Upside: -
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $6.96
Upside: +14.94%
May 1, 2024
Downgrades: Neutral
Price Target: $36 → $13
Current: $12.11
Upside: +7.35%
Apr 25, 2024
Maintains: Overweight
Price Target: $115 → $75
Current: $68.63
Upside: +9.28%
Mar 13, 2024
Upgrades: Overweight
Price Target: $100 → $120
Current: $93.44
Upside: +28.42%
Feb 29, 2024
Maintains: Overweight
Price Target: $40 → $62
Current: $33.66
Upside: +84.19%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $242.54
Upside: +3.08%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $13.60
Upside: +17.65%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.48
Upside: -17.45%
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $187.77
Upside: -3.61%
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $21.80
Upside: +97.25%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $18.00
Upside: -5.56%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $114.23
Upside: +3.30%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $90.39
Upside: +72.59%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $81.03
Upside: +29.58%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $150.88
Upside: -73.49%